Title:
NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES
Document Type and Number:
WIPO Patent Application WO/2023/235267
Kind Code:
A3
Abstract:
The invention includes dry powder nintedanib formulation for dispersion and inhalation administration including salts therof, indolinone derivative or salts thereof and in fixed dose combinations with carrier agents and other active ingredients. The aerosol delivery combination formulation may be administered as an inhaled aerosol over a few actuations or by two or more actuations. Each dose may be administered one or more times daily on a regular or interval daily dosing regimen. The special formulation parameters of the invention include the selection of the salt for complexation with the form of nintedanib used for an isolated dry powder along with particle size distributions and combiniation with a force control agent for improved aerosol delivery. Methods of the invention include therapeutically effective doses of the described invention used to treat intersitital lung disease.
Inventors:
SURBER MARK WILLIAM (US)
PHAM STEPHEN (US)
PHAM STEPHEN (US)
Application Number:
PCT/US2023/023770
Publication Date:
January 04, 2024
Filing Date:
May 26, 2023
Export Citation:
Assignee:
AVALYN PHARMA INC (US)
International Classes:
A61K9/00; A61K9/16; A61K31/496; A61K45/06; A61K47/26; A61P11/00; C07B43/04; C07D209/32; C07D403/12
Domestic Patent References:
| WO2018108669A1 | 2018-06-21 | |||
| WO2019081235A1 | 2019-05-02 | |||
| WO2013144655A1 | 2013-10-03 | |||
| WO2022068876A1 | 2022-04-07 |
Foreign References:
| US20220000772A1 | 2022-01-06 | |||
| US20220087937A1 | 2022-03-24 | |||
| US10154994B2 | 2018-12-18 | |||
| TW202103700A | 2021-02-01 | |||
| US20210361888A1 | 2021-11-25 | |||
| CN112138024A | 2020-12-29 | |||
| US20200085801A1 | 2020-03-19 |
Attorney, Agent or Firm:
MULVILLE, Kurt T. (US)
Download PDF: